Brown, Lisle/Cummings’s Amphastar Pharmaceuticals AMPH Stock Holding History

Brown, Lisle/Cummings’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$529	Buy	+27	New	+$661	﹤0.01%	982

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Brown, Lisle/Cummings's AMPH Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Amphastar Pharmaceuticals (AMPH) in Q1 2026: 27 shares worth $529. The stake represents ﹤0.01% of the portfolio and ranks #982 among its holdings.

215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

Brown, Lisle/Cummings held 27 shares of Amphastar Pharmaceuticals worth $529 as of Q1 2026.
Amphastar Pharmaceuticals was a new Brown, Lisle/Cummings position in Q1 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #982 holding.
215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.